Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxorubicin + trabectedin with or without radiation therapy in advanced gynecologic leiomyosarcoma
KCT0010448Phase 2Not yet recruiting
- Sponsor
- Asan Medical Center
- Start
- Apr 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of doxorubicin, trabectedin in uterine leiomyosarcoma (uLMS), leiomyosarcoma (LMS), soft tissue sarcoma (STS), sponsored by Asan Medical Center. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
doxorubicintrabectedin
03
Conditions
uterine leiomyosarcoma (uLMS)leiomyosarcoma (LMS)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on KCT0010448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0010448.